ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

7 years ago

ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May4, 2018. The following is a summary of the matters voted on at that meeting.

(1) The stockholders elected AbbVie’s ClassIII Directors with terms expiring in 2021, as follows:

Name	For	Against	BrokerNon-Votes
Roxanne S. Austin	1,136,868,599	13,161,295	260,703,800
Richard A. Gonzalez	1,115,140,717	34,889,177	260,703,800
Rebecca B. Roberts	1,139,178,279	10,851,615	260,703,800
Glenn F. Tilton	1,129,746,144	20,283,750	260,703,800

(2) The stockholders ratified the appointment of Ernst& Young LLP as AbbVie’s independent registered public accounting firm for 2018, as follows:

For	Against	Abstain
1,397,789,476	9,779,337	3,164,881

(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2018 annual meeting, as follows:

For	Against	Abstain	BrokerNon-Votes
1,091,537,665	52,278,080	6,214,149	260,703,800

(4) The stockholders approved, on an advisory basis, the frequency of the vote to approve the compensation of AbbVie’s named executive officers, as follows:

1Year	2Years	3Years	Abstain	BrokerNon-Votes
1,119,508,603	5,474,102	19,509,034	5,538,155	260,703,800

(5) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation for the annual election of directors, as follows:

For	Against	Abstain	BrokerNon-Votes
1,142,267,330	4,446,678	3,315,886	260,703,800

(6) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

For	Against	Abstain	BrokerNon-Votes
1,139,337,651	7,165,827	3,526,416	260,703,800

(7) The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows:

For	Against	Abstain	BrokerNon-Votes
272,992,743	848,877,882	28,159,269	260,703,800

(8) The stockholders did not approve a stockholder proposal to separate chair and CEO, as follows:

For	Against	Abstain	BrokerNon-Votes
441,926,892	702,905,620	5,197,382	260,703,800

(9) The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows:

For	Against	Abstain	BrokerNon-Votes
247,879,964	887,590,325	14,559,605	260,703,800

About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.